SCIENTIFIC INDUSTRIES INC
For the period ended Jun 30, 2025. Filed Aug 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 19, 2025
SCNDStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
| For the Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(3,302,200) | $(3,335,200) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 321,000 | 377,300 |
| Stock-based compensation | 375,200 | 530,200 |
| Provision for bad debt | - | 2,000 |
| Loss (gain) on sale of investment securities | (20,100) | 3,500 |
| Unrealized holding (gain) on investment securities | (8,600) | (12,700) |
| Noncash lease expense | 101,600 | 167,400 |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 259,900 | (57,800) |
| Inventories | (147,700) | 88,800 |
| Prepaid and other current assets | (126,400) | (31,200) |
| Income Tax Receivable | - | 87,800 |
| Other assets | 4,300 | - |
| Accounts payable | 36,000 | 500 |
| Contract Liabilities | - | 5,100 |
| Accrued expenses | (149,500) | (94,200) |
| Lease liabilities | (106,400) | (168,300) |
| Net cash used in operating activities | (2,762,900) | (2,436,800) |
| Investing activities: | ||
| Purchase of investment securities | - | (479,000) |
| Redemption of investment securities | 1,613,900 | 2,121,900 |
| Capital expenditures | (33,200) | (72,200) |
| Net cash provided by investing activities | 1,580,700 | 1,570,700 |
| Financing activities: | ||
| Proceeds from issuance of common stock | 1,550,000 | 716,800 |
| Issuance costs of common stock and warrants | (97,800) | (71,100) |
| Net cash provided by financing activities | 1,452,200 | 645,700 |
| Effect of changes in foreign currency exchange rates on cash and cash equivalents | 33,500 | (15,200) |
| Net increase (decrease) in cash and cash equivalents | 303,500 | (235,600) |
| Cash and cash equivalents, beginning of period | 587,900 | 796,100 |
| Cash and cash equivalents, end of period | $891,400 | $560,500 |
See notes to unaudited condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.